Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

Tandem Diabetes Care begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with diabetes ...

Abbott Laboratories has initiated a voluntary recall of a small number of FreeStyle Libre 3 sensors within three lots distributed throughout the US. Designed to be what the company says is the world’s ...

Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for incorrect high glucose readings. After parts of her large intestine died and ...